OCULUS joins International Myopia Institute in mission to raise myopia awareness

Article

OCULUS has combined efforts with International Myopia Institute to raise awareness of myopia and drive scientific advancements to prevent sight-threatening complications and blindness, which may arise as a result.

OCULUS joins International Myopia Institute in mission to raise myopia awareness

OCULUS has joined forces with the International Myopia Institute (IMI) to raise awareness of myopia and will support research activities to prevent future vision impairment and loss.

“We are delighted about the cooperation,” said Christian Kirchhübel, CEO of OCULUS. “Our mission at OCULUS is to support eye care professionals around the world with cutting-edge, high-tech development. We are dedicated to saving and improving vision and visual performance with our precise, reliable long-lasting measurement solutions.”

OCULUS

OCULUS is an ophthalmic device company, providing sophisticated technology to meet the daily challenges that eye care professionals encounter. It was established in 1895 as a family business and continues to be managed by third and fourth generations. All devices are designed and manufactured at the OCULUS headquarters in Wetzlar, Germany, and there are 12 subsidiaries in Europe, Asia and America.

International Myopia Institute

The International Myopia Institute was formed in 2015 to address the increasing levels of myopia and high myopia, which may lead to sight-threatening complications. The group of global experts aim to advance research, patient management, and education in myopia to prevent future vision impairment and blindness associated with nearsightedness. Made up of scientists, clinicians, policy makers, government officials, and educators, the IMI create white papers and clinical summaries and make them available worldwide in a variety of languages.

“We are thrilled to have OCULUS join in our mission to advance research, patient management and education in myopia,” said Dr Monica Jong, IMI Executive Director. “Open collaboration and sharing of knowledge globally with eye care practitioners (ECPs) are critical to prevent future myopia-related vision impairment and blindness. We will continue to bring the latest, evidence-based information directly to ECPs across the world which would not be possible without our industry supporters.”

Related Content: Cataract & Refractive | Inflammation & Infection | Paediatrics

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.